SCHEMBL535388

SCHEMBL535388

CCCC(=O)n1nnc2ccccc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.59
ALDH1A1 P00352 2/20 0.59
MEN1 O00255 1/20 0.59
HPGD P15428 3/20 0.57
HSD17B10 Q99714 2/20 0.57
MAPT P10636 2/20 0.57
ALOX15 P16050 1/20 0.57
ASAH1 Q13510 1/20 0.57
GAA P10253 11/20 0.55
MGAM O43451 10/20 0.55
AMY1A P0DUB6 10/20 0.55
SI P14410 10/20 0.55
MGAM2 Q2M2H8 10/20 0.55
F2 P00734 2/20 0.55
SLC9A1 P19634 2/20 0.55
LMNA P02545 2/20 0.53
HTT P42858 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
MITF O75030 1/20 0.53
TSHR P16473 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23780256 0.91 KMT2A (0.62) KMT2AALDH1A1MEN1HPGDHSD17B10
SCHEMBL535030 0.89 ASAH1 (0.64) KMT2AALDH1A1MEN1HPGDHSD17B10
SCHEMBL18206302 0.88 ASAH1 (0.66) KMT2AALDH1A1MEN1HPGDHSD17B10
SCHEMBL534984 0.88 ASAH1 (0.66) KMT2AALDH1A1MEN1HPGDHSD17B10
SCHEMBL5793440 0.88 ASAH1 (0.66) KMT2AALDH1A1MEN1HPGDHSD17B10
SCHEMBL534899 0.88 ASAH1 (0.66) KMT2AALDH1A1MEN1HPGDHSD17B10
SCHEMBL535029 0.88 ASAH1 (0.66) KMT2AALDH1A1MEN1HPGDHSD17B10
SCHEMBL337266 0.88 ASAH1 (0.66) KMT2AALDH1A1MEN1HPGDHSD17B10
SCHEMBL535094 0.88 ASAH1 (0.66) KMT2AALDH1A1MEN1HPGDHSD17B10
SCHEMBL13134139 0.87 GAA (0.58) KMT2AALDH1A1HPGDHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186433-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF EPIVARIO, INC. 2025-06-12 US disclosed
US-12133852-B2 ACSS2 inhibitors and methods of use thereof EPIVARIO, INC. (US) 2024-11-05 US disclosed
US-20230102379-A1 CITRUS HUANGLONGBING THERAPEUTIC COMPOUNDS POINT LOMA NAZARENE UNIVERSITY 2023-03-30 US disclosed
US-20220305010-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2022-09-29 US disclosed
CN-114008025-A ACSS2 inhibitors and methods of use thereof 美特波米德有限公司 2022-02-01 CN disclosed
WO-2021150951-A1 CITRUS HUANGLONGBING THERAPEUTIC COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-07-29 WO disclosed
WO-2021150951-A1 CITRUS HUANGLONGBING THERAPEUTIC COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-07-29 WO disclosed
WO-2020230136-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD (IL) 2020-11-19 WO disclosed
EP-1952918-B1 METHOD FOR PRODUCING METAL PARTICLE DISPERSION, CONDUCTIVE INK USING METAL PARTICLE DISPERSION PRODUCED BY SUCH METHOD, AND CONDUCTIVE COATING FILM TOYO INK MFG CO (JP) 2013-05-22 EP disclosed
US-8440110-B2 Method for producing metal particle dispersion, conductive ink using metal particle dispersion produced by such method, and conductive coating film TOYO INK MFG CO., LTD. (JP) 2013-05-14 US disclosed
EP-1990377-B1 COLORED METALLIC PIGMENT, PROCESS FOR PRODUCING THE SAME, AND COATING COMPOSITION AND COSMETIC PREPARATION CONTAINING SAID COLORED METALLIC PIGMENT TOYO ALUMINIUM KK (JP) 2012-02-08 EP disclosed
US-7998266-B2 Colored metallic pigment, process for producing the same, and coating composition and cosmetic preparation containing said colored metallic pigment TOYO ALUMINIUM KABUSHIKI KAISHA (JP) 2011-08-16 US disclosed
US-20110175040-A1 METHOD FOR PRODUCING METAL PARTICLE DISPRESION, CONDUCTIVE INK USING METAL PARTICLE DISPERSION PRODUCED BY SUCH METHOD, AND CONDUCTIVE COATING FILM TOYO INK MFG CO., LTD. (JP) 2011-07-21 US disclosed
US-7981327-B2 Method for producing metal particle dispersion, conductive ink using metal particle dispersion produced by such method, and conductive coating film TOYO INK MFG. CO. LTD. (JP) 2011-07-19 US disclosed
US-20090258202-A1 Method for Producing Metal Particle Dispersion, Conductive Ink Using Metal Particle Dispersion Produced by Such Method, and Conductive Coating Film GVP GESELLSCHAFT ZUR VERMARKTUNG DER PORENBRENNERTECHNIK MBH (DE) 2009-10-15 US disclosed
US-20090017082-A1 COLORED METALLIC PIGMENT, PROCESS FOR PRODUCING THE SAME, AND COATING COMPOSITION AND COSMETIC PREPARATION CONTAINING SAID COLORED METALLIC PIGMENT TOYO ALUMINIUM KABUSHIKI KAISHA (JP) 2009-01-15 US disclosed
EP-1990377-A1 COLORED METALLIC PIGMENT, PROCESS FOR PRODUCING THE SAME, AND COATING COMPOSITION AND COSMETIC PREPARATION COMPRISING SAID COLORED METALLIC PIGMENT TOYO ALUMINIUM KABUSHIKI KAISHA (JP) 2008-11-12 EP disclosed
EP-1952918-A1 METHOD FOR PRODUCING METAL PARTICLE DISPERSION, CONDUCTIVE INK USING METAL PARTICLE DISPERSION PRODUCED BY SUCH METHOD, AND CONDUCTIVE COATING FILM Toyo Ink Mfg. Co., Ltd (JP) 2008-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230102379-A1 CITRUS HUANGLONGBING THERAPEUTIC COMPOUNDS LSS, REL, RPN1 KMT2A 2885/4885ALDH1A1 1897/4885MEN1 3542/4885
US-20250186433-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, GLS2, ADSS2 KMT2A 1401/4885ALDH1A1 238/4885MEN1 1305/4885
US-20220305010-A1 ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, GLS2, ADSS2 KMT2A 1401/4885ALDH1A1 238/4885MEN1 1305/4885
US-12133852-B2 ACSS2 inhibitors and methods of use thereof ACSS2, GLS2, ADSS2 KMT2A 1401/4885ALDH1A1 238/4885MEN1 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.